Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q15369
UPID:
ELOC_HUMAN
Alternative names:
Elongin 15 kDa subunit; RNA polymerase II transcription factor SIII subunit C; SIII p15; Transcription elongation factor B polypeptide 1
Alternative UPACC:
Q15369; E5RGD9; Q567Q6
Background:
Elongin-C, known for its role in transcription elongation, enhances RNA polymerase II's ability to transcribe past arresting sites. It forms a crucial part of the elongin BC complex, contributing to the regulation of pluripotent stem cells by generating chromatin regions with both active and repressive properties. Additionally, Elongin-C is a core component of various E3 ubiquitin-protein ligase complexes, mediating the ubiquitination of target proteins, including the von Hippel-Lindau ubiquitination complex CBC(VHL).
Therapeutic significance:
Understanding the role of Elongin-C could open doors to potential therapeutic strategies.